drugset / Trial / NCT01266135
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of QAX576 in patients with idiopathic pulmonary fibrosis.
Timeline
- Start
- 2010-12
- Primary completion
- 2013-04
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QAX576 | Monoclonal antibody | 10 mg/kg | Intravenous |